WallStreetZenWallStreetZen

NYSEMKT: ATNM
Actinium Pharmaceuticals Inc Stock

$7.32+0.21 (+2.95%)
Updated Jul 22, 2024
ATNM Price
$7.32
Fair Value Price
N/A
Market Cap
$218.01M
52 Week Low
$4.00
52 Week High
$10.24
P/E
-4.28x
P/B
4.97x
P/S
2,695.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$81.00k
Earnings
-$46.45M
Gross Margin
100%
Operating Margin
-57,346.91%
Profit Margin
-57,346.9%
Debt to Equity
1.02
Operating Cash Flow
-$40M
Beta
0.7
Next Earnings
Aug 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ATNM Overview

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies. Its lead product candidate is Iomab-B, which is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, for the treatment of patients with penta refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ATNM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ATNM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ATNM is good value based on its book value relative to its share price (4.97x), compared to the US Biotechnology industry average (6.3x)
P/B vs Industry Valuation
ATNM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ATNM due diligence checks available for Premium users.

Be the first to know about important ATNM news, forecast changes, insider trades & much more!

Valuation

ATNM price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.28x
Industry
-27.86x
Market
29.85x

ATNM price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.97x
Industry
6.3x
ATNM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ATNM's financial health

Profit margin

Revenue
$0.0
Net Income
-$8.7M
Profit Margin
0%
ATNM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ATNM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$88.4M
Liabilities
$44.5M
Debt to equity
1.02
ATNM's short-term assets ($85.37M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATNM's short-term assets ($85.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATNM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATNM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.4M
Investing
-$11.0k
Financing
$14.8M
ATNM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ATNM vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ATNM$218.01M+2.95%-4.28x4.97x
GNFT$217.78M+5.05%-6.94x2.95x
PYXS$217.30M+6.03%-2.71x1.18x
CYBN$216.62M-5.00%-1.57x1.02x
GLUE$221.24M+2.82%-1.75x1.45x

Actinium Pharmaceuticals Stock FAQ

What is Actinium Pharmaceuticals's quote symbol?

(NYSEMKT: ATNM) Actinium Pharmaceuticals trades on the NYSEMKT under the ticker symbol ATNM. Actinium Pharmaceuticals stock quotes can also be displayed as NYSEMKT: ATNM.

If you're new to stock investing, here's how to buy Actinium Pharmaceuticals stock.

What is the 52 week high and low for Actinium Pharmaceuticals (NYSEMKT: ATNM)?

(NYSEMKT: ATNM) Actinium Pharmaceuticals's 52-week high was $10.24, and its 52-week low was $4.00. It is currently -28.52% from its 52-week high and 83% from its 52-week low.

How much is Actinium Pharmaceuticals stock worth today?

(NYSEMKT: ATNM) Actinium Pharmaceuticals currently has 29,783,451 outstanding shares. With Actinium Pharmaceuticals stock trading at $7.32 per share, the total value of Actinium Pharmaceuticals stock (market capitalization) is $218.01M.

Actinium Pharmaceuticals stock was originally listed at a price of $45.00 in Dec 27, 2012. If you had invested in Actinium Pharmaceuticals stock at $45.00, your return over the last 11 years would have been -83.73%, for an annualized return of -15.22% (not including any dividends or dividend reinvestments).

How much is Actinium Pharmaceuticals's stock price per share?

(NYSEMKT: ATNM) Actinium Pharmaceuticals stock price per share is $7.32 today (as of Jul 22, 2024).

What is Actinium Pharmaceuticals's Market Cap?

(NYSEMKT: ATNM) Actinium Pharmaceuticals's market cap is $218.01M, as of Jul 23, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Actinium Pharmaceuticals's market cap is calculated by multiplying ATNM's current stock price of $7.32 by ATNM's total outstanding shares of 29,783,451.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.